Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 292

1.

BRAF genetic heterogeneity in papillary thyroid carcinoma and its metastasis.

Walts AE, Pao A, Sacks W, Bose S.

Hum Pathol. 2014 May;45(5):935-41. doi: 10.1016/j.humpath.2013.12.005.

PMID:
24746198
2.

BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.

Costa AM, Herrero A, Fresno MF, Heymann J, Alvarez JA, Cameselle-Teijeiro J, García-Rostán G.

Clin Endocrinol (Oxf). 2008 Apr;68(4):618-34.

PMID:
18070147
3.

Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression.

Gandolfi G, Sancisi V, Torricelli F, Ragazzi M, Frasoldati A, Piana S, Ciarrocchi A.

J Clin Endocrinol Metab. 2013 May;98(5):E934-42. doi: 10.1210/jc.2012-3930.

PMID:
23533235
4.

Prediction of occult central lymph node metastasis in papillary thyroid carcinoma by preoperative BRAF analysis using fine-needle aspiration biopsy: a prospective study.

Joo JY, Park JY, Yoon YH, Choi B, Kim JM, Jo YS, Shong M, Koo BS.

J Clin Endocrinol Metab. 2012 Nov;97(11):3996-4003. doi: 10.1210/jc.2012-2444.

PMID:
22930785
5.

BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid <or=1 cm and their paired lymph node metastases.

Rodolico V, Cabibi D, Pizzolanti G, Richiusa P, Gebbia N, Martorana A, Russo A, Amato MC, Galluzzo A, Giordano C.

Cancer. 2007 Sep 15;110(6):1218-26.

6.

Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metastases from well-differentiated thyroid carcinomas.

Erickson LA, Jin L, Nakamura N, Bridges AG, Markovic SN, Lloyd RV.

Cancer. 2007 May 15;109(10):1965-71.

7.

Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.

Lukas J, Drabek J, Dudesek B, Vazan P, Stranska J, Jancik S, Mackova M, Syrucek M, Lukas D, Duskova J, Dundr P, Hintnausova B, Jiskra J.

Exp Clin Endocrinol Diabetes. 2014 May;122(5):268-72. doi: 10.1055/s-0034-1372624.

PMID:
24839220
8.

BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness.

Kurtulmus N, Duren M, Ince U, Cengiz Yakicier M, Peker O, Aydın O, Altiok E, Giray S, Azizlerli H.

Endocrine. 2012 Oct;42(2):404-10.

PMID:
22426956
9.

BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer.

Howell GM, Nikiforova MN, Carty SE, Armstrong MJ, Hodak SP, Stang MT, McCoy KL, Nikiforov YE, Yip L.

Ann Surg Oncol. 2013 Jan;20(1):47-52. doi: 10.1245/s10434-012-2611-0.

PMID:
22941165
10.

The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma.

Giannini R, Ugolini C, Lupi C, Proietti A, Elisei R, Salvatore G, Berti P, Materazzi G, Miccoli P, Santoro M, Basolo F.

J Clin Endocrinol Metab. 2007 Sep;92(9):3511-6.

PMID:
17535994
11.

Association between BRAF V600E mutation and regional lymph node metastasis in papillary thyroid carcinoma.

Lu J, Gao J, Zhang J, Sun J, Wu H, Shi X, Teng L, Liang Z.

Int J Clin Exp Pathol. 2015 Jan 1;8(1):793-9.

12.

BRAF V600E mutation in papillary thyroid carcinoma: significant association with node metastases and extra thyroidal invasion.

Chakraborty A, Narkar A, Mukhopadhyaya R, Kane S, D'Cruz A, Rajan MG.

Endocr Pathol. 2012 Jun;23(2):83-93. doi: 10.1007/s12022-011-9184-5.

PMID:
22105775
13.

Papillary microcarcinoma of the thyroid: clinical characteristics and BRAF(V600E) mutational status of 977 cases.

Zheng X, Wei S, Han Y, Li Y, Yu Y, Yun X, Ren X, Gao M.

Ann Surg Oncol. 2013 Jul;20(7):2266-73. doi: 10.1245/s10434-012-2851-z.

PMID:
23370668
14.

The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome?

Walczyk A, Kowalska A, Kowalik A, Sygut J, Wypiórkiewicz E, Chodurska R, Pięciak L, Góźdź S.

Clin Endocrinol (Oxf). 2014 Jun;80(6):899-904. doi: 10.1111/cen.12386.

PMID:
24354346
15.

BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment.

Begum S, Rosenbaum E, Henrique R, Cohen Y, Sidransky D, Westra WH.

Mod Pathol. 2004 Nov;17(11):1359-63.

16.

MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse.

Renaud F, Gnemmi V, Devos P, Aubert S, Crépin M, Coppin L, Ramdane N, Bouchindhomme B, d'Herbomez M, Van Seuningen I, Do Cao C, Pattou F, Carnaille B, Pigny P, Wémeau JL, Leteurtre E.

Thyroid. 2014 Sep;24(9):1375-84. doi: 10.1089/thy.2013.0594.

PMID:
25012490
17.

Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma.

Kim J, Giuliano AE, Turner RR, Gaffney RE, Umetani N, Kitago M, Elashoff D, Hoon DS.

Ann Surg. 2006 Nov;244(5):799-804.

18.

Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation.

Yip L, Nikiforova MN, Carty SE, Yim JH, Stang MT, Tublin MJ, Lebeau SO, Hodak SP, Ogilvie JB, Nikiforov YE.

Surgery. 2009 Dec;146(6):1215-23. doi: 10.1016/j.surg.2009.09.011.

PMID:
19958951
19.

BRAF(V600E) mutation and the biology of papillary thyroid cancer.

Frasca F, Nucera C, Pellegriti G, Gangemi P, Attard M, Stella M, Loda M, Vella V, Giordano C, Trimarchi F, Mazzon E, Belfiore A, Vigneri R.

Endocr Relat Cancer. 2008 Mar;15(1):191-205. doi: 10.1677/ERC-07-0212.

20.

Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma.

Fisher KE, Jani JC, Fisher SB, Foulks C, Hill CE, Weber CJ, Cohen C, Sharma J.

J Surg Res. 2013 Nov;185(1):217-24. doi: 10.1016/j.jss.2013.05.003.

Items per page

Supplemental Content

Support Center